Literature DB >> 8660310

Identification of the domains of neuronal nitric oxide synthase by limited proteolysis.

P N Lowe1, D Smith, D K Stammers, V Riveros-Moreno, S Moncada, I Charles, A Boyhan.   

Abstract

Nitric oxide synthase (EC 1.14.13.39) binds arginine and NADPH as substrates, and FAD, FMN, tetrahydrobiopterin, haem and calmodulin as cofactors. The protein consists of a central calmodulin-binding sequence flanked on the N-terminal side by a haem-binding region, analogous to cytochrome P-450, and on the C-terminal side by a region homologous with NADPH:cytochrome P-450 reductase. The structure of recombinant rat brain nitric oxide synthase was analysed by limited proteolyis. The products were identified by using antibodies to defined sequences, and by N-terminal sequencing. Low concentrations of trypsin produced three fragments, similar to those in a previous report [Sheta, McMillan and Masters (1994) J. Biol. Chem. 269, 15147-15153]: that of Mr approx. 135000 (N-terminus Gly-221) resulted from loss of the N-terminal extension (residues 1-220) unique to neuronal nitric oxide synthase. The fragments of Mr 90000 (haem region) and 80000 (reductase region, N-terminus Ala-728) were produced by cleavage within the calmodulin-binding region. With more extensive trypsin treatment, these species were shown to be transient, and three smaller, highly stable fragments of Mr 14000 (N-terminus Leu-744 within the calmodulin region), 60000 (N-terminus Gly-221) and 63000 (N-terminus Lys-856 within the FMN domain) were formed. The species of Mr approx. 60000 represents a domain retaining haem and nitroarginine binding. The two species of Mr 63000 and 14000 remain associated as a complex. This complex retains cytochrome c reductase activity, and thus is the complete reductase region, yet cleaved at Lys-856. This cleavage occurs within a sequence insertion relative to the FMN domain present in inducible nitric oxide synthase. Prolonged proteolysis treatment led to the production of a protein of Mr approx. 53000 (N-terminus Ala-953), corresponding to a cleavage between the FMN and FAD domains. The major products after chymotryptic digestion were similar to those with trypsin, although the pathway of intermediates differed. The haem domain was smaller, starting at residue 275, yet still retained the arginine binding site. These data have allowed us to identify stable domains representing both the arginine/haem-binding and the reductase regions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660310      PMCID: PMC1217052          DOI: 10.1042/bj3140055

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

1.  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase.

Authors:  D S Bredt; P M Hwang; C E Glatt; C Lowenstein; R R Reed; S H Snyder
Journal:  Nature       Date:  1991-06-27       Impact factor: 49.962

2.  Coding nucleotide, 5' regulatory, and deduced amino acid sequences of P-450BM-3, a single peptide cytochrome P-450:NADPH-P-450 reductase from Bacillus megaterium.

Authors:  R T Ruettinger; L P Wen; A J Fulco
Journal:  J Biol Chem       Date:  1989-07-05       Impact factor: 5.157

3.  NADPH-cytochrome P-450 oxidoreductase: flavin mononucleotide and flavin adenine dinucleotide domains evolved from different flavoproteins.

Authors:  T D Porter; C B Kasper
Journal:  Biochemistry       Date:  1986-04-08       Impact factor: 3.162

4.  Characterization of a catalytically self-sufficient 119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in Bacillus megaterium.

Authors:  L O Narhi; A J Fulco
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

5.  The binding of riboflavin-5'-phosphate in a flavoprotein: flavodoxin at 2.0-Angstrom resolution.

Authors:  K D Watenpaugh; L C Sieker; L H Jensen
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

6.  Cloning of the gene encoding a catalytically self-sufficient cytochrome P-450 fatty acid monooxygenase induced by barbiturates in Bacillus megaterium and its functional expression and regulation in heterologous (Escherichia coli) and homologous (Bacillus megaterium) hosts.

Authors:  L P Wen; A J Fulco
Journal:  J Biol Chem       Date:  1987-05-15       Impact factor: 5.157

7.  Identification and characterization of two functional domains in cytochrome P-450BM-3, a catalytically self-sufficient monooxygenase induced by barbiturates in Bacillus megaterium.

Authors:  L O Narhi; A J Fulco
Journal:  J Biol Chem       Date:  1987-05-15       Impact factor: 5.157

8.  Processing of adenovirus 2-induced proteins.

Authors:  C W Anderson; P R Baum; R F Gesteland
Journal:  J Virol       Date:  1973-08       Impact factor: 5.103

9.  Characterization of recombinant Bacillus megaterium cytochrome P-450 BM-3 and its two functional domains.

Authors:  H Y Li; K Darwish; T L Poulos
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

10.  Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide.

Authors:  E A Emini; J V Hughes; D S Perlow; J Boger
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  11 in total

1.  Characterization of a nitric oxide synthase from the plant kingdom: NO generation from the green alga Ostreococcus tauri is light irradiance and growth phase dependent.

Authors:  Noelia Foresi; Natalia Correa-Aragunde; Gustavo Parisi; Gonzalo Caló; Graciela Salerno; Lorenzo Lamattina
Journal:  Plant Cell       Date:  2010-11-30       Impact factor: 11.277

2.  Dissociation and unfolding of inducible nitric oxide synthase oxygenase domain identifies structural role of tetrahydrobiopterin in modulating the heme environment.

Authors:  Rajib Sengupta; Rupam Sahoo; Sougata Sinha Ray; Tanmay Dutta; Anjan Dasgupta; Sanjay Ghosh
Journal:  Mol Cell Biochem       Date:  2006-01-13       Impact factor: 3.396

3.  Cysteine-200 of human inducible nitric oxide synthase is essential for dimerization of haem domains and for binding of haem, nitroarginine and tetrahydrobiopterin.

Authors:  R R Cubberley; W K Alderton; A Boyhan; I G Charles; P N Lowe; R W Old
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

4.  Delineation of the arginine- and tetrahydrobiopterin-binding sites of neuronal nitric oxide synthase.

Authors:  A Boyhan; D Smith; I G Charles; M Saqi; P N Lowe
Journal:  Biochem J       Date:  1997-04-01       Impact factor: 3.857

5.  Nitroarginine and tetrahydrobiopterin binding to the haem domain of neuronal nitric oxide synthase using a scintillation proximity assay.

Authors:  W K Alderton; A Boyhan; P N Lowe
Journal:  Biochem J       Date:  1998-05-15       Impact factor: 3.857

Review 6.  Nitric oxide synthases: structure, function and inhibition.

Authors:  W K Alderton; C E Cooper; R G Knowles
Journal:  Biochem J       Date:  2001-08-01       Impact factor: 3.857

7.  Metallothionein-3 and neuronal nitric oxide synthase levels in brains from the Tg2576 mouse model of Alzheimer's disease.

Authors:  Bruce L Martin; Abigail M Tokheim; Patrick T McCarthy; Brendan S Doms; Andrew A Davis; Ian M Armitage
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

8.  Expression of nitric oxide synthase isoforms in pregnant human myometrium.

Authors:  S R Bartlett; P R Bennett; J S Campa; W J Dennes; D M Slater; G E Mann; L Poston; R Poston
Journal:  J Physiol       Date:  1999-12-15       Impact factor: 5.182

9.  Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives.

Authors:  Haitao Ji; Silvia L Delker; Huiying Li; Pavel Martásek; Linda J Roman; Thomas L Poulos; Richard B Silverman
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

Review 10.  Role of neuronal nitric oxide synthase on cardiovascular functions in physiological and pathophysiological states.

Authors:  Ahmmed Ally; Isabella Powell; Minori M Ally; Kevin Chaitoff; Surya M Nauli
Journal:  Nitric Oxide       Date:  2020-06-23       Impact factor: 4.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.